Assessment and Significance of Allograft Rejection in Heart Transplantation using HistoMap and Formalin Fixed Paraffin Embedded Tissue
CareDx Jun 1, 2023 - Apr 30, 2024
Role: Co-Investigator
Description: The goal of this study is the evaluate the utility of digital spatial profiling in different forms of acute rejection in heart transplant patients. |
Identification of tissue cellular and transcriptomic signature for improving diagnostic sensitivity for cardiac sarcoidosis
NIH/NCATS/ACTRI May 1, 2023 - Apr 30, 2024
Role: Principal Investigator
Description: The goal of this study is to improve the diagnostic sensitivity of endomyocardial biopsies for cardiac sarcoidosis through identification of a unique transcriptomic signature. |
Development of non-invasive cell-free DNA to supplant invasive biopsy in heart transplantation (DEFINE-HT)
Natera Apr 1, 2023 - Oct 30, 2024
Role: Site Principal Investigator
Description: Prospective multicenter observational study evaluating the use of donor derived cell-free DNA in the detection of acute rejection in heart transplant patients |
4D Compressed Sensing Flow
NIH/NCATS/ACTRI Dec 1, 2022 - Apr 30, 2023
Role: Co-Investigator |
KL2TR001444
NIH/NCATS KL2TR001444Dec 1, 2020 - Nov 30, 2023
Role: Principal Investigator
Description: The goal of this study is understanding of immunotolerance and allograft longevity in heart-transplant patients. |
Use of dd-cfDNA to Detect Rejection in Cardiac Allograft Patients
Natera Nov 1, 2020 - Feb 1, 2022
Role: Site Principal Investigator
Description: To measure and statistically compare dd-cfDNA levels between 2 groups of cardiac transplant patients defined by biopsy results: Clinical Group 1 with no signs of rejection and Clinical Group 2 where any kind of rejection (any grade) is found, and compare these values to those measured using the same assay in a general population cohort, as found in published literature. |
Surveillance HeartCare Outcomes Registry (SHORE)
CareDx Jun 1, 2019 - May 31, 2024
Role: Site Principal Investigator
Description: The primary study objective is to assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients. |
Identifying an Immune-mediated Mechanism in Nonspecific Allograft Dysfunction of Heart-Transplant Patients
NIH/NCATS/ACTRI Oct 15, 2018 - Oct 7, 2019
Role: Principal Investigator
Description: We will attempt to identify an immune-mediated mechanism in nonspecific graft dysfunction of heart-transplant patients. The life after heart transplantation is limited by gradual weakening of the heart after transplant with an average survival of 10 years. We currently do not know the cause in up to 40% of heart-transplant patients, called nonspecific graft dysfunction, and patients with nonspecific graft dysfunction are at much higher risk for death. We will focus our research on T cells, a type of white blood cell. T cells have been shown to cause weakening of the heart in heart-transplant patients in different ways. We believe there is another way that T cells cause disease that is not prevented by our current medications. We will use new, cutting-edge technology to analyze individual T cells in heart-transplant patients to understand why some patients develop nonspecific graft dysfunction. These findings will be critical to improving our understanding of heart-transplant biology and most importantly, preventing heart failure in transplant patients and improving their lives. |
Evaluation of Myocardial Perfusion and Immune Cell Response in Allograft Dysfunction of Heart-Transplant Patients
AHA 18CDA34110250Jul 1, 2018 - Jun 30, 2021
Role: Principal Investigator
Description: The goal of this study is evaluation of abnormal hearts after heart-transplantation in patients |
Evaluation of Allograft Dysfunction in Heart-Transplant Patients
Astellas Pharma Investigator Initiated Study Apr 1, 2017 - Dec 28, 2018
Role: Principal Investigator |